Takeda Pharmaceutical (NYSE:TAK – Get Free Report) and Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.
Volatility and Risk
Takeda Pharmaceutical has a beta of -0.02, suggesting that its stock price is 102% less volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.91, suggesting that its stock price is 91% more volatile than the S&P 500.
Profitability
This table compares Takeda Pharmaceutical and Zentalis Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Takeda Pharmaceutical | 8.26% | 11.51% | 5.59% |
| Zentalis Pharmaceuticals | N/A | -75.82% | -55.15% |
Insider and Institutional Ownership
9.2% of Takeda Pharmaceutical shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Takeda Pharmaceutical and Zentalis Pharmaceuticals”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Takeda Pharmaceutical | $4,693.24 billion | 0.01 | -$1.01 billion | $0.76 | 28.20 |
| Zentalis Pharmaceuticals | $67.43 million | 1.81 | -$137.06 million | ($1.92) | -0.89 |
Zentalis Pharmaceuticals has lower revenue, but higher earnings than Takeda Pharmaceutical. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Takeda Pharmaceutical and Zentalis Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Takeda Pharmaceutical | 0 | 1 | 2 | 1 | 3.00 |
| Zentalis Pharmaceuticals | 1 | 1 | 7 | 1 | 2.80 |
Zentalis Pharmaceuticals has a consensus price target of $8.29, suggesting a potential upside of 387.39%. Given Zentalis Pharmaceuticals’ higher probable upside, analysts plainly believe Zentalis Pharmaceuticals is more favorable than Takeda Pharmaceutical.
Summary
Takeda Pharmaceutical beats Zentalis Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
About Takeda Pharmaceutical
Takeda Pharmaceutical Company is a Japan-based global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Founded in Osaka in 1781 as a medicine wholesaler, it has grown into an international pharmaceutical business headquartered in Tokyo. The company focuses on gastroenterology and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Its portfolio includes treatments for conditions such as inflammatory bowel disease and hereditary angioedema, along with medicines and vaccines across its other therapeutic areas.
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for cancer. Its research centers on therapies that target biological processes involved in tumor growth. The company’s lead drug candidate, azenosertib (formerly known as ZN-c3), is an investigational inhibitor of WEE1, a protein involved in cell-cycle regulation. It has been studied in clinical trials for ovarian cancer and other solid tumors. Zentalis has also advanced other oncology drug candidates, including compounds targeting cancer-related proteins.
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
